LOSS OF HETEROZYGOSITY OF TUMOR-SUPPRESSOR GENES IN TESTIS CANCER

被引:0
|
作者
PENG, HQ
BAILEY, D
BRONSON, D
GOSS, PE
HOGG, D
机构
[1] TORONTO HOSP, DIV ONCOL RES, TORONTO, ON M5G 2C4, CANADA
[2] TORONTO HOSP, DEPT PATHOL, TORONTO, ON M5G 2C4, CANADA
[3] UNIV MINNESOTA, SCH MED, DEPT UROL, MINNEAPOLIS, MN 55455 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Little is known of the molecular changes that occur in germ cell tumors (GCT) of the testis. We studied three GCT cell lines and 44 tumors for loss of heterozygosity (LOH) of the tumor suppressor genes APC, MCC, DCC, RE, TP53, and WT-1. We observed that LOH occurred in 55% (21 of 38) of informative cases at DCC, in 28% (10 of 36) of informative cases at APC,in 23% (6 of 26) at MCC, in 30% (13 of 43) at RB, and in 27% (6 of 22) at WT-1. The LOH level in these tumors using anonymous primers mapping to the short and long arms of chromosome 19, which is cytogenetically normal in GCT, revealed LOH of 11 and 5%, respectively. We also observed a LOH of 22% in the TP53 gene, despite the fact that mutations in TP53 do not occur in testis cancer. Since a high frequency of LOH at DCC (18q21.3) occurs equally at all histological subsets in GCT, we conclude that the loss of the function of this gene is an early event in testicular GCTs. However, the observed LOH levels at APC/MCC (5q21), RE (13q14), and WT-1 (11p13) could represent a functional loss of the corresponding tumor suppressor gene in some GCTs or reflect the loss of sequences in the same general chromosome region but involving a different tumor suppressor locus. Therefore, detailed mapping of these chromosomes is required to define the precise locations of maximal LOH in testis cancer.
引用
收藏
页码:2871 / 2875
页数:5
相关论文
共 50 条
  • [41] TUMOR-SUPPRESSOR GENES IN DISEASE AND THERAPY
    SKUSE, GR
    LUDLOW, JW
    LANCET, 1995, 345 (8954): : 902 - 906
  • [42] HUMAN PAPILLOMAVIRUSES, TUMOR-SUPPRESSOR GENES AND CERVICAL-CANCER
    INMAN, GJ
    COOK, ID
    LAU, RKW
    INTERNATIONAL JOURNAL OF STD & AIDS, 1993, 4 (03) : 128 - 134
  • [43] SOMATIC AND GERMINAL MUTATIONS OF TUMOR-SUPPRESSOR GENES IN THE DEVELOPMENT OF CANCER
    SASAKI, MS
    KATO, M
    TOGUCHIDA, J
    YAMAGUCHI, T
    EJIMA, Y
    ISHIZAKI, K
    KANEKO, A
    TANOOKA, H
    JOURNAL OF RADIATION RESEARCH, 1991, 32 : 266 - 276
  • [44] Animal models of tumor-suppressor genes
    Hakem, R
    Mak, TW
    ANNUAL REVIEW OF GENETICS, 2001, 35 : 209 - 241
  • [45] TUMOR-SUPPRESSOR GENES IN UROLOGIC TUMORS
    WOLFF, JM
    HABIB, FK
    UROLOGY, 1993, 42 (04) : 461 - 466
  • [46] MOLECULAR-GENETICS OF CANCER - ONCOGENES AND TUMOR-SUPPRESSOR GENES
    BUDILLON, A
    CANCER, 1995, 76 (10) : 1869 - 1873
  • [47] TUMOR-SUPPRESSOR GENES IN PROSTATIC ONCOGENESIS
    BOOKSTEIN, R
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 217 - 223
  • [48] Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents
    Wang, Hong
    Han, Haiyong
    Mousses, Spyro
    Von Hoff, Daniel D.
    SEMINARS IN ONCOLOGY, 2006, 33 (04) : 513 - 520
  • [49] LOSS OF HETEROZYGOSITY (LOH) PUTATIVE TUMOR SUPPRESSOR GENES LOCI IN LOCALLY METASTATIC PROSTATE-CANCER
    SAKR, WA
    MACOSKA, J
    BENSON, P
    PONTES, JE
    CRISSMAN, JD
    WOLMAN, SR
    LABORATORY INVESTIGATION, 1993, 68 (01) : A68 - A68
  • [50] Analysis of Loss of Heterozygosity for Tumor-Suppressor Genes Can Accurately Classify and Predict the Clinical Behavior of Mucinous Tumors Arising From the Appendix
    Vivek Maheshwari
    Allan Tsung
    Yan Lin
    Herb J. Zeh
    Sydney D. Finkelstein
    David L. Bartlett
    Annals of Surgical Oncology, 2006, 13 : 1610 - 1616